Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer

Cancer

Volumn 107, Issue 11, 2006, Pages 2597-2603

  Tsai, Henry K ^a   Chen, Ming Hui ^b   McLeod, David G ^c   Carroll, Peter R ^d,f   Richie, Jerome P ^e   D'Amico, Anthony V ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Mortality; Outcome; Prostate carcinoma; Radical prostatectomy; Radiotherapy

Indexed keywords

BICALUTAMIDE; DOCETAXEL; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; COHORT ANALYSIS; DISEASE COURSE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SHORT COURSE THERAPY; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; ANILIDES; COHORT STUDIES; FLUTAMIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 33751566977     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22279     Document Type: Article

References (24)

1. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766-771.
2. Zelefsky MI, Leibel SA, Gandin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491-500.
3. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 1999;281:1598-1604.
4. D'Amico AV, Whittington R, Malkowicz, SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002;95:281-286.
5. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schnitz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 2002;20:4567-4573.
6. Freedland SI, Humphreys KB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439.
7. Roach M 3rd, Lu J, Pilepich MV et al. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys. 2000;47:617-627.
8. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21:2163-2172.
9. Lubeck DP, Litwin MS, Henning JM, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1996;48:773-777.
10. Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPSURE), a national disease registry. J Urol. 2004;171:1393-1401.
11. Gleason DF. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic Pathology, Philadelphia: Lea & Febiger; 1977:171-197.
12. Greene FL, Page DL, Fleming ID, et al., editors. American Joint Committee on Cancer: Manual for Staging Cancer, 6th ed. New York: Springer-Verlag; 2002.
13. Fine IP Gray RJ, A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
14. Gaynor JJ, Feur EJ, Tan CC. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993;88:400-409.
15. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
16. Hsu JC. Multiple Comparisons: Theory and Methods. London: Chapman & Hall; 1996.
17. Buyyounouski MK, Hanlon AL, Horwitz LM, Uzzo RG, Pollack A. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. Int J Radiat Oncol Biol Phys. 2005;61:1291-1298.
18. Petrylak DR Tangen CM, Hussein MH, et al. Docetaxel and estramustine compared with miloxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
19. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
20. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000;23:3904-3911.
21. Zietman AL, De Silvio ML, Slater JD, et al. Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233-1230.
22. Smith EB, Frierson HF Jr., Mills SE, Boyd JC, Theodorescu D. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer. 2002;94:2282-2287.
23. Ghani KK, Grigor K, Tulloch DN, Bollina PR, McNeill SA. Trends in reporting Gleason score 1991 to 2001: changes in the pathologist's practice. Eur Urol. 2005;47:196-201.
24. Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005;97:1248-1253.